CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $2.13B, above the global median of $1.18B
- FinancialsAltman Z-Score 6.6: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
203.10BINR2.13B · vs all stocks (USD)
Trailing P/E
37.02xRevenue (TTM)
50.92BINR533.69M · vs all stocks (USD)
Profit Margin
10.71%Beta
-0.0240xvs all stocks
52-Week Change
62.47%vs all stocks
Market Capitalization
203.10BINR2.13B · vs all stocks (USD)
Enterprise Value
152.47BINR1.60B · vs all stocks (USD)
Trailing P/E
37.02xForward P/E
27.75xPrice to Sales (TTM)
3.97xPrice to Book (MRQ)
5.07xEnterprise to Revenue
2.99xEnterprise to EBITDA
14.84xGross Margin
65.34%Profit Margin
10.71%Operating Margin
16.90%Return on Assets (TTM)
7.71%Return on Equity (TTM)
11.70%Revenue (TTM)
50.92BINR533.69M · vs all stocks (USD)
Revenue per Share (TTM)
209.94INRUpdated Aug 29, 2026Quarterly Revenue Growth
22.00%Gross Profit (TTM)
31.52BINR330.33M · vs all stocks (USD)
EBITDA (TTM)
12.84BINR134.52M · vs all stocks (USD)
Net Income (TTM)
5.45BINR57.17M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
27.70%Operating Cash Flow (TTM)
7.93BINR83.13M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
5.95BINR62.36M · vs all stocks (USD)
5-Year Average Dividend Yield
0.36%vs all stocks
Payout Ratio
6.67%Revenue
53.39BINRFY2026 · Mar 31, 2026Cost of Goods Sold
20.16BINRFY2026 · Mar 31, 2026Gross Profit
33.23BINRFY2026 · Mar 31, 2026Operating Income
9.01BINR94.39M · vs all stocks (USD)
Pre-tax Income
7.85BINRFY2026 · Mar 31, 2026Income Tax Expense
1.90BINRFY2026 · Mar 31, 2026Net Income
5.95BINRFY2026 · Mar 31, 2026EBIT
8.56BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
11.74BINRFY2026 · Mar 31, 2026Research & Development
2.85BINRFY2026 · Mar 31, 2026Selling, General & Administrative
5.19BINRFY2026 · Mar 31, 2026Other Operating Expenses
4.40BINRFY2026 · Mar 31, 2026Non-operating Interest Income
70.44MINRFY2026 · Mar 31, 2026Non-operating Interest Expense
714.31MINRFY2026 · Mar 31, 2026EPS (Basic)
24.47INRFY2026 · Mar 31, 2026EPS (Diluted)
24.46INRFY2026 · Mar 31, 2026Basic Shares Outstanding
243.16MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
243.16MSharesFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
9.16BINRFY2026 · Mar 31, 2026Free Cash Flow
3.62BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
8.80BINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
7.85BINRFY2026 · Mar 31, 2026Stock-based Compensation
0.00INRFY2026 · Mar 31, 2026Other Non-cash Items
1.07BINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
1.45BINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-1.21BINRFY2026 · Mar 31, 2026Capital Expenditures
-5.55BINRFY2026 · Mar 31, 2026Net Acquisitions
-3.27BINRFY2026 · Mar 31, 2026Sale of Investments
1.03BINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-7.79BINRFY2026 · Mar 31, 2026Long-term Debt Issuance
6.47MINRFY2026 · Mar 31, 2026Long-term Debt Payments
-1.11BINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
-550.71MINRFY2026 · Mar 31, 2026Common Dividends Paid
-363.97MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
4.66BINRFY2026 · Mar 31, 2026Shares Outstanding
242.67MSharesUpdated Aug 29, 2026Float Shares
142.43MSharesUpdated Aug 29, 2026% Held by Insiders
40.15%vs all stocks
% Held by Institutions
22.97%vs all stocks
Total Cash (MRQ)
6.19BINR64.87M · vs all stocks (USD)
Total Cash per Share (MRQ)
25.51INRUpdated Aug 29, 2026Total Debt (MRQ)
18.07BINR189.37M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4537xCurrent Ratio (MRQ)
1.80xBook Value per Share (MRQ)
164.06INRUpdated Aug 29, 2026Total Assets
77.20BINR809.05M · vs all stocks (USD)
Total Current Assets
37.68BINRFY2026 · Mar 31, 2026Total Liabilities
26.35BINRFY2026 · Mar 31, 2026Total Non-current Assets
39.52BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
5.43BINRFY2026 · Mar 31, 2026Total Current Liabilities
20.92BINRFY2026 · Mar 31, 2026Cash
4.58BINRFY2026 · Mar 31, 2026Cash Equivalents
4.22BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
8.80BINRFY2026 · Mar 31, 2026Other Short-term Investments
530.56MINRFY2026 · Mar 31, 2026Accounts Receivable
9.09BINRFY2026 · Mar 31, 2026Inventory
16.73BINRFY2026 · Mar 31, 2026Accounts Payable
6.73BINRFY2026 · Mar 31, 2026Short-term Debt
10.54BINRFY2026 · Mar 31, 2026Other Current Liabilities
111.92MINRFY2026 · Mar 31, 2026Long-term Debt
4.58BINRFY2026 · Mar 31, 2026Common Stock (Book)
247.80MINRFY2026 · Mar 31, 2026Retained Earnings
36.18BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
50.85BINR532.91M · vs all stocks (USD)
52-Week Low
494.00INRUpdated Aug 29, 202652-Week High
910.00INRUpdated Aug 29, 202652-Week Change
62.47%vs all stocks
Beta
-0.0240xvs all stocks
50-Day MA
579.02INRUpdated Aug 29, 2026200-Day MA
526.46INRUpdated Aug 29, 2026Avg 10-Day Volume
21.63KSharesUpdated Aug 29, 2026Avg 30-Day Volume
30.11KSharesUpdated Aug 29, 2026Diluted EPS (TTM)
22.49INRUpdated Aug 29, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 6.6: safe zoneNotable
Altman Z-Score: 6.60
High earnings qualityNotable
Earnings Quality Score: 0.50
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $2.13B, above the global median of $1.18BNotable
Market cap (USD): 2,128,504,612.047Global Median: 1,180,223,658.953
Levered free cash flow is $62.36M, above the global median of $18.73MNotable
Levered free cash flow (USD): 62,358,200.8Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Bausch Health Companies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ocular Therapeutix Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangzhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Healthgen Biotechnology Corp.
Tier 1ProductionApproval-Gated PipelineRule
Guobang Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pell Bio-Med Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Adma Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ligachem Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Fujian Cosunter Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule